Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 217, Issue 5, Pages -Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20200653
Keywords
-
Categories
Funding
- Intramural Research Program of the National Cancer Institute/National Institutes of Health
- National Institutes of Health [R01AI39512, R21AG064479-01, 1R01 AI121066, 1R01DK115217, NIAID-DAIT-NIHAI201700100]
- Brain Health Research Institute Pilot Award from Kent State University
- Sir Henry Dale Fellowship from the Royal Society
- Wellcome Trust [206200/Z/17/Z, FC001206]
- Francis Crick Institute from Cancer Research UK [FC001206]
- UK Medical Research Council [FC001206]
- UKMedical Research Council
- King's College London/Francis Crick Institute partnership
- MRC [MC_U117597139] Funding Source: UKRI
- Wellcome Trust [206200/Z/17/Z] Funding Source: Wellcome Trust
Ask authors/readers for more resources
With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-lambda) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-lambda to prevent, limit, and treat these dangerous viral infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
